clinical trial · NCT06510816
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Geographic AtrophyVonaprumentSham Administration
brief summary
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.
started
Jul 30, 2024
primary completion
Oct 31, 2026
completion
Jul 31, 2027
last updated
May 4, 2026
official title
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 (Vonaprument) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol